ALVEOFACT® 45 mg/ml 54 mg clinical trials

Proof-of-principle study of inhaled pulmonary surfactant in patients with Idiopathic Pulmonary Fibrosis (INSURF-IPF)

This study explores a new inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if a special lung surfactant can improve how well your lungs work. Researchers will monitor lung function and safety in adults with IPF.